. 2021 Apr 10;13(8):1814. doi: 10.3390/cancers13081814

Table 1.

Summary of diagnostic metrics for discriminating EGFR, KRAS, ERBB2, and TP53 mutations.

True Label		Radiomic Features						Combined Model (Radiomic Features and Clinical Factors)
True Label		Wildtype	Mutation	Sensitivity	Specificity	Accuracy	AUC	Wildtype	Mutation	Sensitivity	Specificity	Accuracy	AUC
EGFR	Wildtype (n = 69)	57	12	0.63(0.50–0.74)	0.83(0.71–0.90)	0.73(0.65–0.80)	0.77(0.70–0.85)	66	3	0.52(0.40–0.65)	0.96(0.87–0.99)	0.75(0.66–0.82)	0.78(0.70–0.86)
EGFR	Mutation (n = 65)	24	41	0.63(0.50–0.74)	0.83(0.71–0.90)	0.73(0.65–0.80)	0.77(0.70–0.85)	31	34	0.52(0.40–0.65)	0.96(0.87–0.99)	0.75(0.66–0.82)	0.78(0.70–0.86)
KRAS	Wildtype (n = 119)	49	70	0.93(0.66–0.99)	0.41(0.32–0.51)	0.47(0.38–0.56)	0.70(0.57–0.83)	81	38	0.87(0.58–0.97)	0.68(0.59–0.76)	0.70(0.62- 0.78)	0.81(0.69–0.93)
KRAS	Mutation (n = 15)	1	14	0.93(0.66–0.99)	0.41(0.32–0.51)	0.47(0.38–0.56)	0.70(0.57–0.83)	2	13	0.87(0.58–0.97)	0.68(0.59–0.76)	0.70(0.62- 0.78)	0.81(0.69–0.93)
ERBB2	Wildtype (n = 121)	42	79	1.00(0.72–1.00)	0.65(0.56–0.74)	0.69(0.60–0.76)	0.88(0.80–0.96)	88	33	0.92(0.62–0.99)	0.73(0.64–0.80)	0.75(0.66–0.82)	0.87(0.78–0.95)
ERBB2	Mutation (n = 13)	0	13	1.00(0.72–1.00)	0.65(0.56–0.74)	0.69(0.60–0.76)	0.88(0.80–0.96)	1	12	0.92(0.62–0.99)	0.73(0.64–0.80)	0.75(0.66–0.82)	0.87(0.78–0.95)
TP53	Wildtype (n = 74)	49	25	0.80(0.67–0.89)	0.66(0.54–0.77)	0.72(0.64- 0.80)	0.78(0.71–0.86)	58	16	0.82(0.69–0.90)	0.78(0.67–0.87)	0.80(0.72–0.87)	0.84(0.78–0.91)
TP53	Mutation (n = 60)	12	48	0.80(0.67–0.89)	0.66(0.54–0.77)	0.72(0.64- 0.80)	0.78(0.71–0.86)	11	49	0.82(0.69–0.90)	0.78(0.67–0.87)	0.80(0.72–0.87)	0.84(0.78–0.91)

EGFR = epidermal growth factor receptor; KRAS = Kirsten rat sarcoma viral oncogene; ERBB2 = Erb-B2 receptor tyrosine kinase 2; TP53 = tumor protein 53